Alkem Laboratories Limited (ALKEM)
ISIN: - Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
2931.15
-55.15(-1.85%)

Alkem Laboratories Limited, a pharmaceutical company, develops, manufactures, and sells pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, diabetology, cardiology, gastroenterology, osteoporosis, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain relief/analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. Alkem Laboratories Limited was incorporated in 1973 and is headquartered in Mumbai, India.

Pricing Updates

TODAY'S HIGH

2999

TODAY'S LOW

2909.65

52 WEEK HIGH

4070

52 WEEK LOW

2828

Major Holders

% of Shares Held by
All Insider

74.50%

% of Shares Held by
Institutions

16.15%

% of Float Held by
Institutions

63.32%

Number of Institutions
Holding Shares

83

Company Overview

MARKET CAP

35046.29 Cr.

ETERPRISE VALUE

36052 Cr.

NO. OF SHARES

11.95 Cr.

BOOK VALUE

722.635

DIV. YIELD

4%

DEBT

2668.18 Cr.

GROSS PROFIT

6453.90 Cr.

CASH

2717.88 Cr.

REVENUE

10634.19 Cr.

REVENUE/SHARE

889.381

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments-1205.11 Cr.-928.62 Cr.-445.39 Cr.166.22 Cr.
Change To Liabilities334.49 Cr.212.42 Cr.-3.74 Cr.-10.95 Cr.
Total cashflows from Investing Activities-1435.13 Cr.-998.54 Cr.-741.35 Cr.-316.39 Cr.
Net Borrowings841.61 Cr.116.65 Cr.583.77 Cr.-105.73 Cr.
Total Cash from Financing Activities379.57 Cr.-271.75 Cr.79.15 Cr.-378.94 Cr.
Other Liabilities15.44 Cr.-30.12 Cr.-104.28 Cr.63.83 Cr.
Total Assets0000
Net Income1645.62 Cr.1585.02 Cr.1127.07 Cr.760.51 Cr.
Change in Cash57.96 Cr.-1.72 Cr.-73.11 Cr.82.34 Cr.
Effect of Exchange Rate2.50 Cr.3.67 Cr.4.01 Cr.-1.98 Cr.
Total Cash from Operating Activities1111.02 Cr.1264.90 Cr.585.08 Cr.779.65 Cr.
Depreciation303.96 Cr.264.82 Cr.243.61 Cr.185.17 Cr.
Other Cashflows from Investing Activities97.96 Cr.79.43 Cr.51.68 Cr.44.32 Cr.
Dividends Paid-421.91 Cr.-334.78 Cr.-358.68 Cr.-179.34 Cr.
Change to Inventory-673.14 Cr.-497.70 Cr.-281.74 Cr.-37.30 Cr.
Change to Account Receivables-221.75 Cr.-25.76 Cr.-257.44 Cr.-155.85 Cr.
Other Cashflows from Financing Activities-40.13 Cr.-53.62 Cr.-145.94 Cr.-93.87 Cr.
Change to Net Income-293.60 Cr.-253.54 Cr.-147.55 Cr.-33.77 Cr.
Capital Expenditures-338.88 Cr.-194.91 Cr.-363.09 Cr.-529.16 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax1844.28 Cr.1842.10 Cr.1259.79 Cr.954.66 Cr.
Minority Interest209.43 Cr.181.28 Cr.148.30 Cr.132.61 Cr.
Net Income1748.96 Cr.1674.77 Cr.1266.02 Cr.941.70 Cr.
Selling General Administrative1962.71 Cr.1980.72 Cr.2085.26 Cr.1872.82 Cr.
Gross Profit6453.90 Cr.5289.90 Cr.4921.07 Cr.4339.43 Cr.
Ebit1748.96 Cr.1674.77 Cr.1266.02 Cr.941.70 Cr.
Operating Income1748.96 Cr.1674.77 Cr.1266.02 Cr.941.70 Cr.
Other Operating Expenses2438.27 Cr.1360.81 Cr.1318.02 Cr.1333.01 Cr.
Interest Expense-52.37 Cr.-39.87 Cr.-46.61 Cr.-42.77 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense163.96 Cr.224.33 Cr.110.48 Cr.181.02 Cr.
Total Revenue10634.19 Cr.8865.01 Cr.8344.36 Cr.7357.19 Cr.
Total Operating Expenses8885.23 Cr.7190.24 Cr.7078.34 Cr.6415.49 Cr.
Cost of Revenue4180.29 Cr.3575.11 Cr.3423.29 Cr.3017.76 Cr.
Total Other Income Expense Net95.32 Cr.167.33 Cr.-6.23 Cr.12.96 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.1680.32 Cr.1617.77 Cr.1149.31 Cr.773.64 Cr.
Net Income Applicable to Common Shares1645.62 Cr.1585.02 Cr.1127.07 Cr.760.51 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets211.54 Cr.84.44 Cr.98.39 Cr.44.26 Cr.
Capital Surplus0000
Total Liabilities5221.86 Cr.3961.25 Cr.3634.36 Cr.2636.24 Cr.
Stock Holder Equity8637.90 Cr.7376.73 Cr.6160.67 Cr.5439.34 Cr.
Minority Interest209.43 Cr.181.28 Cr.148.30 Cr.132.61 Cr.
Other Liabilities1039.62 Cr.195.99 Cr.202.11 Cr.138.21 Cr.
Total Assets14069.19 Cr.11519.26 Cr.9943.33 Cr.8208.19 Cr.
Common Stock23.91 Cr.23.91 Cr.23.91 Cr.23.91 Cr.
Retained Earnings07354 Cr.6103.74 Cr.5409.47 Cr.
Other Liabilities340.67 Cr.259.56 Cr.231.81 Cr.187.41 Cr.
Good Will403.09 Cr.395.39 Cr.398.45 Cr.380.56 Cr.
Treasury Stock8613.99 Cr.-1.18 Cr.33.02 Cr.5.96 Cr.
Other Assets2160.88 Cr.1245.60 Cr.1064.38 Cr.860.89 Cr.
Cash2578.58 Cr.174.22 Cr.175.94 Cr.249.05 Cr.
Current Liabilities4805.34 Cr.3604.05 Cr.3243.31 Cr.2217.53 Cr.
Long Term Asset Charges1309.26 Cr.1107.91 Cr.932.57 Cr.707.63 Cr.
Short Long Term Debt2570.74 Cr.36.83 Cr.38.10 Cr.41.50 Cr.
Other Stockholder Equity8613.99 Cr.-1.18 Cr.33.02 Cr.5.96 Cr.
Property Plant Equipment2626.58 Cr.2706.43 Cr.2774.14 Cr.2598.58 Cr.
Total Cur. Assets8435.43 Cr.6928.82 Cr.5496.03 Cr.4216.13 Cr.
Long Term Investments231.67 Cr.158.58 Cr.111.94 Cr.107.77 Cr.
Net Tangible Assets8023.27 Cr.6896.90 Cr.5663.83 Cr.5014.52 Cr.
Short Term Investments139.31 Cr.1412.34 Cr.116.27 Cr.178.10 Cr.
Net Receivables2078 Cr.1921.33 Cr.1910.95 Cr.1408.73 Cr.
Long Term Debt9.38 Cr.27.93 Cr.67.59 Cr.224.98 Cr.
Inventory3005.53 Cr.2312.44 Cr.1818.82 Cr.1499.87 Cr.
Accounts Payable1173.38 Cr.1069.41 Cr.954.05 Cr.962.25 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account